Stock Events

Stock Events

Xenetic Biosciences 

$3.86
27
-$0.11-2.77% 17:36 Today

Statistics

Day High
4.02
Day Low
3.91
52W High
10.36
52W Low
2.02
Volume
10,622
Avg. Volume
36,598
Mkt Cap
9.04M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.72
-0.55
-0.37
-0.2
Expected EPS
N/A
Actual EPS
N/A

Financials

-90.09%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.98MRevenue
-2.68MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XBIO. It's not an investment recommendation.
AMC Entertainment
5
AMC
BlackBerry
5
BB
Palantir Technologies
3
PLTR
Dogecoin
3
DOGE.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics is involved in gene editing, a field that overlaps with Xenetic's work on drug delivery and biosciences, making them direct competitors in the biotech innovation space.
Editas Medicine
EDIT
Mkt Cap477.63M
Editas Medicine operates in the genome editing sector, directly competing with Xenetic Biosciences in the development of gene therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a leading company in CRISPR/Cas9 technology for genome editing, competing in the same biotech and gene therapy space as Xenetic.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.91B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, potentially competing with Xenetic in the rare disease market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.61B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing in the broader biotech space for novel drug delivery systems like Xenetic.
Beam Therapeutics
BEAM
Mkt Cap3.07B
Beam Therapeutics specializes in precision genetic medicines through base editing, a form of gene editing competing with Xenetic's bioscience approaches.
Voyager Therapeutics
VYGR
Mkt Cap208.88M
Voyager Therapeutics focuses on the development of gene therapies for neurodegenerative diseases, potentially competing with Xenetic in gene therapy delivery technologies.

About

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Show more...
CEO
James F. Parslow
Employees
2
Country
United States
ISIN
US9840156023
WKN
000A3EFQB

Listings

MU
DE
3XB0.MU
STU
DE
3XB0.STU
STU
DE
3XB.STU
BOATS
BOATS
XBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Xenetic Biosciences stock price today?▼
The current price of XBIO is $3.86 USD — it has decreased by -2.77% in the past 24 hours. Watch Xenetic Biosciences stock price performance more closely on the chart.
What is Xenetic Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Xenetic Biosciences stocks are traded under the ticker XBIO.
Is Xenetic Biosciences stock price growing?▼
XBIO stock has risen by +7.52% compared to the previous week, the month change is a +54.4% rise, over the last year Xenetic Biosciences has showed a +35.44% increase.
What is Xenetic Biosciences market cap?▼
Today Xenetic Biosciences has the market capitalization of 9.04M
When is the next Xenetic Biosciences earnings date?▼
Xenetic Biosciences is going to release the next earnings report on November 06, 2026.
What were Xenetic Biosciences earnings last quarter?▼
XBIO earnings for the last quarter are -0.41 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xenetic Biosciences revenue for the last year?▼
Xenetic Biosciences revenue for the last year amounts to 2.98M USD.
What is Xenetic Biosciences net income for the last year?▼
XBIO net income for the last year is -2.68M USD.
How many employees does Xenetic Biosciences have?▼
As of August 28, 2026, the company has 2 employees.
In which sector is Xenetic Biosciences located?▼
Xenetic Biosciences operates in the Health & Wellness sector.
When did Xenetic Biosciences complete a stock split?▼
The last stock split for Xenetic Biosciences was on May 15, 2023 with a ratio of 1:10.
Where is Xenetic Biosciences headquartered?▼
Xenetic Biosciences is headquartered in FRAMINGHAM, United States.